The STAT3 inhibitor Stattic was also able to decrease fibrosis in BM-MSCs from MPN patients (data not shown), but further experiments are needed to assess its effect on TGFβ-induced fibrosis in the absence of aberrantly active JAK/STAT signaling. Here, TGFB1 is linked to myeloproliferative disorder.